The U.S. Food and Drug Administration has cleared the way for the world's first study of human embryonic stem cell therapy, Geron Corp said on Friday.
The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord injury. Reuters
Unsurprisingly, the article made no mention of the hundreds of techniques and successes made possible by the use of adult and placenta/stem cord stem cell research that does not require the killing of human embryos.
Post a Comment